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Objective To evaluate outcome trends of neonates born very preterm in 11 high-income countries participating in
the International Network for Evaluating Outcomes of neonates.
Study design In a retrospective cohort study, we included 154 233 neonates admitted to 529 neonatal units be-
tween January 1, 2007, and December 31, 2015, at 240/7 to 316/7 weeks of gestational age and birth weight <1500 g.
Composite outcomes were in-hospital mortality or any of severe neurologic injury, treated retinopathy of prematu-
rity, and bronchopulmonary dysplasia (BPD); and same composite outcome excluding BPD. Secondary outcomes
were mortality and individual morbidities. For each country, annual outcome trends and adjusted relative risks
comparing epoch 2 (2012-2015) to epoch 1 (2007-2011) were analyzed.
Results For composite outcome including BPD, the trend decreased in Canada and Israel but increased in
Australia and New Zealand, Japan, Spain, Sweden, and the United Kingdom. For composite outcome excluding
BPD, the trend decreased in all countries except Spain, Sweden, Tuscany, and the United Kingdom. The risk of
composite outcome was lower in epoch 2 than epoch 1 in Canada (adjusted relative risks 0.78; 95% CI
0.74-0.82) only. The risk of composite outcome excluding BPD was significantly lower in epoch 2 compared withFrom the 1Department of Newborn Care, Royal Hospital
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Switzerland. Mortality rates reduced in most countries in epoch 2. BPD
rates increased significantly in all countries except Canada, Israel,
Finland, and Tuscany.
Conclusions In most countries, mortality decreased whereas BPD
increased for neonates born very preterm. (J Pediatr 2019;215:32-40).
N
eonates born very preterm at <32 weeks of gestational age or at a very
low birth weight (<1500 g) have a high risk of mortality and morbidity,
including neurodevelopmental problems.1-3 Adverse long-term health
outcomes contribute significantly to increased financial costs to both health sys-
tems and families.4 Many countries have established national registries and net-
works that benchmark outcomes of neonates born very preterm.5-10 Evaluating
mortality and morbidity trends within specific populations over time can help
identify targets for improvement.11-13 Furthermore, quality improvement initia-
tives using registries for site-level reports, trend analysis, and case review can fos-
ter collaborative learning, improve outcomes, and reduce costs.14,15
The International Network for Evaluation of Outcomes (iNeo) of neonates
was established to develop collaboration between networks/registries that have
population-based or national datasets. Eleven high-income countries/regions
with neonatal datasets agreed to participate and contribute data to iNeo with
the goal to identify care practices that improve neonatal outcomes and identify(www.jpeds.com).
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BPD Bronchopulmonary dysplasia
iNeo International Network for Evaluation of Outcomes of neonates
NICU Neonatal intensive care unit
ROP Retinopathy of prematurity
SNI Severe neurologic injury
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Volume 215  December 2019areas for possible improvement.11 Previously, we reported a
significant variation in outcomes between the participating
iNeo countries16 as well as differences in some practices.17-21
In this study, our aim was to analyze trends in the health
outcomes of neonates born very preterm in 11 high-
income countries. The impetus for this comparison came
from iNeo objectives to understand variation, foster discus-
sion and collaboration, and identify areas for improvement
through the assessment of changes in neonatal outcomes
within countries over time.Methods
In our retrospective cohort study, neonates born between
January 1, 2007, and December 31, 2015, weighing <1500 g
at 240/7 to 316/7 weeks of gestational age, and admitted to a
neonatal intensive care unit (NICU) participating in a na-
tional neonatal network/registry included in iNeo were
eligible. Neonates who were born at <24 weeks of gestational
age, ³32 weeks of gestational age, or had major congenital
anomalies were excluded. Neonates <24 weeks of gestational
age were excluded because resuscitation practices for neo-
nates who are 22 and 23 weeks of gestational age vary within
both units and countries.22 The cohort data from 2007 to
2015 were divided in 2 epochs of approximately similar num-
ber of neonates to assess change over time. The 2 epochs were
used instead of year as a continuous variable because fluctu-
ations in annual outcome rates in smaller countries/region
may have a large effect on statistical estimates unless data
from a few years were combined together.
Our study included data from 11 high-income countries with
10 independent neonatal networks/registries that participate in
the iNeo. The iNeo dataset contains deidentified individual pa-
tient data for neonates admitted to 29 Australian and New Zea-
land Neonatal Network units, 28 Canadian Neonatal Network
units, 28 Finnish Medical Birth Register units, 27 Israel
Neonatal Network units, 159Neonatal ResearchNetwork Japan
units, 50 Spanish Neonatal Network units, 37 Swedish Neonatal
Quality Register units, 10 Swiss Neonatal Network units, 4 Tus-
cany Neonatal Network units, and 103 United Kingdom
Neonatal Collaborative units. Data were only available from
2008 to 2015 for the United Kingdom Neonatal Collaborative
and from 2009 to 2015 for the Tuscany Neonatal Network.Data Source and Definitions
The countries participating in iNeo agreed to share a defined
set of variables.11 Gestational age was defined according to
the best available information within each country. Early ul-
trasound scan or last menstrual period were used in majority
of cases to determine gestational age. We compared propor-
tions of total admissions at each gestational age in weeks in
each country to check distribution of patients. Any adminis-
tration of corticosteroids before birth, regardless of drug,
timing, or dose, was classified as receipt of antenatal steroids.
A country-specific birth weight standard was used to calcu-
late the birth weight z score for each neonate.23Outcome Measures
We evaluated 2 composite outcomes, 1 with BPD and 1
without because the diagnosis of BPD was the most variable
outcome definition between countries: in-hospital mortality
or any of 3 major morbidities including severe neurologic
injury (SNI), treated retinopathy of prematurity (ROP), and
bronchopulmonary dysplasia (BPD); and the same composite
outcome but excluding BPD. We evaluated SNI, ROP, and
BPD in our composite outcome because they were reported
consistently by all networks and associatedwith neurodevelop-
mental outcomes.We did not include necrotizing enterocolitis
or infection in the composite outcome because debate around
their diagnosis led to high variability among countries.
Secondary outcomes were mortality, SNI, treated ROP, or
BPD individually. Mortality was defined as death before
discharge. Delivery room deaths were not included because
of differential data collection methods. SNI included grade 3
or greater peri-intraventricular hemorrhage24 or persistent
periventricular echodensity/echolucency, but not cerebellar
hemorrhage or injury as they were not consistently evaluated
by all units. Receipt of either laser surgery or intraocular injec-
tions of antivascular endothelial growth factor agents was clas-
sified as treated ROP.25 BPDwas defined as a supplementation
of oxygen at 36 weeks of postmenstrual age or discharge.
Statistical Analyses
We divided the cohort in 2 epochs with a similar number of
neonates: epoch 1 included births between January 1, 2007,
and December 31, 2011; epoch 2 included births between
January 1, 2012, and December 31, 2015. We evaluated
annual adjusted trends for the outcomes within each country
using the Cochran–Armitage trend test and reported these as
a significant (P <.05) increase or decrease. We compared
baseline characteristics and composite and individual out-
comes within each country between the 2 epochs and re-
ported the frequency (percentage) or mean (SD). We
assessed differences between the epochs by Pearson c2 for
categorical variables and Student t test for continuous vari-
ables. We applied multivariable Poisson regressions to assess
the epoch effect across countries with adjustments. We esti-
mated adjusted risk ratios and 95% CIs for outcome change
between epoch 1 and epoch 2 for both composite outcomes.
We adjusted for birth weight z score (calculated using
country-specific birthweight charts for gestational age and
sex), sex, andmultiple births and did not include any practice
related variables (eg, cesarean delivery, antenatal steroid
administration, or Apgar scores).
We calculated standardized ratios for the composite
outcome using the “indirect standardization” approach, strat-
ified by epoch. The expected numbers of neonates with out-
comes for each individual country were calculated from the
multivariable logistic regression model constructed on the
rest of the dataset. We applied Bonferroni correction for pair-
wise comparisons across countries. Standardized ratio esti-
mates and the 99% CI for both epochs for each individual
country were displayed graphically. We conducted all analyses
using SAS 9.4 (SAS Institute Inc, Cary, North Carolina).33
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Results
Of the total 200 472 neonates in the dataset, 154 233 were
eligible for this study. A total of 46 239 neonates were
excluded from the analysis: 6970 were <24 weeks of gesta-
tional age, 33 379 were ³32 weeks of gestational age, and
5890 had major congenital anomalies. The rates of multiple
births and outborn neonates were significantly lower in
epoch 2 (2012 and 2015) than epoch 1 (2007-2011), and rates
of cesarean delivery, antenatal steroid use, and Apgar score of
<7 at 5 minutes were significantly greater in epoch 2 than
epoch 1 (Table I). Given the known variation in care
practices and outcomes at <26 weeks of gestational age, we
identified that Switzerland and Tuscany had a lower
percentage of neonates admitted at <26 weeks of
gestational age than other countries (Table II; available at
www.jpeds.com). Tuscany also had the greatest percentage
of neonates admitted at 30 and 31 weeks of gestational age
of all countries. There was no clinically significant change
in distribution of neonates at each gestational age over the
years (Table III; available at www.jpeds.com).
The composite outcome rate including BPD increased by
1.9% across all countries in epoch 2, whereas the composite
outcome excluding BPD decreased by 1.8% (Table IV). The
mortality rate decreased between the epochs by 1.7 percentage
points, and all countries except Israel reduced their mortality
rate between epoch 1 and epoch 2. All individual outcomes
were lower in epoch 2 than epoch 1 except for BPD, which
increased by 4.2%. The rate of BPD increased in epoch 2 in
all countries except Canada and Finland.
Analysis of outcome trends over the study period showed
that the composite outcome including BPD decreased in
Canada and Israel over the study period, whereas it
increased in Australia and New Zealand, Japan, Spain,
Sweden, and the United Kingdom (Figure 1 and Table V
[available at www.jpeds.com]). The trend for Switzerland,
Finland, and Tuscany did not significantly change
throughout the study period; however, Switzerland had
the lowest composite outcome rates of all countries for
most of the study period. For the composite outcome
excluding BPD a decreasing trend was observed in all
countries except Spain, Sweden, Tuscany, and the United
Kingdom, where there was no significant difference. The
trends for mortality and individual morbidities also were
analyzed (Figures 2-5 and Tables VI-IX; available at
www.jpeds.com).
For the composite outcome including BPD, Canada had a
significantly lower adjusted relative risk in epoch 2 than
epoch 1; however, the risk of the composite outcome was
greater in Australia–New Zealand, Japan, Spain, Sweden,
and the United Kingdom (Table X). For the composite34outcome excluding BPD, Australia–New Zealand, Canada,
Finland, Japan, and Switzerland had a significantly lower
risk in epoch 2 than epoch 1, whereas there was no
statistically significant change in the rest of the countries.
The risk of mortality was lower in epoch 2 than in epoch 1
in all countries, but the improvement was insignificant in
Israel, Sweden, Switzerland, and Tuscany (Table X). The
risk of SNI was significantly lower in epoch 2 than epoch 1
in Australia–New Zealand and Japan but greater in Spain
and the United Kingdom. Spain and United Kingdom had
a significantly greater risk of treated ROP in epoch 2 than
epoch 1, whereas Canada, Israel, and Japan had a lower risk
of treated ROP. The risk of BPD was lower in epoch 2 than
epoch 1 in Canada but higher in Australia–New Zealand,
Japan, Spain, Sweden, and the United Kingdom, which was
the driver for the increased composite outcome including
BPD in those countries.
Overall, the standardized ratio of the composite outcome
improved in Canada and Israel in epoch 2 compared with
epoch 1 (Figure 6; available at www.jpeds.com). The
United Kingdom and Spain had a high standardized ratio
in both epochs, whereas Australia and New Zealand,
Finland, Japan, and Tuscany had low standardized ratios.
Discussion
In this large international cohort from 11 countries, we iden-
tified that mortality and major morbidities decreased be-
tween 2007 and 2015 in most countries. However, there
was an increase in BPD in most countries except Canada.
Subtle differences in population characteristics were identi-
fied that may or may not explain these differences.
The strengths of our study are a high-risk, large, interna-
tional, multiple country cohort; a standardized reporting sys-
tem within each country; and a focus on within country
comparisons. In addition, we used both composite outcome
(including and excluding BPD) and individual outcomes for
comparison, as it may be possible that a unit/country may
have a lower morbidity rate but greater mortality rate.
Without the use of a composite outcome such detail will be
missed, and it is important that neonates survive without
any morbidity.
Our study has limitations. First, due to inconsistencies in
data availability between the countries, our composite
outcome did not include 2 other commonly reported and
important outcomes: necrotizing enterocolitis and late-
onset sepsis. Second, we excluded neonates born at <24 weeks
of gestational age. This was pre-planned because there are
marked variations in resuscitation and active care in neonates
at these gestational ages. However, we must acknowledge that
minor differences in rates of neonates admitted at
24-26 weeks of gestational age persisted, which may have re-
sulted in baseline differences in outcome rates as this gesta-
tional age group is at high risk of adverse outcomes. Third,
because some countries did not collect these data, we
excluded neonates who were stillborn, not admitted to aLui et al
Table I. Infant characteristics in countries participating in iNeo
Characteristics Epoch ANZNN CNN FinMBR INN NRNJ SEN1500 SNQ SwissNeoNet Tuscan NN UKNC Total P value
Number of infants Total 22 331 20 783 2627 10 050 30343 18 257 5351 4895 1465 38 131 154 233 NA
1* 12 161 11 068 1560 5577 16 633 10 273 2700 2575 675 17 584 80 806
2† 10 170 9715 1067 4473 13 710 7984 2651 2320 790 20 547 73 427
Gestational age, wk,
mean (SD)
Total 27.9 (2.1) 27.7 (2.1) 27.9 (2.1) 28.1 (2.1) 27.8 (2.1) 28.1 (2.1) 27.7 (2.1) 28.0 (2.0) 28.2 (2.2) 27.8 (2.1) 27.9 (2.1)
1* 27.8 (2.1) 27.7 (2.0) 27.9 (2.0) 28.1 (2.1) 27.8 (2.1) 28.1 (2.1) 27.8 (2.1) 28.0 (2.0) 28.2 (2.2) 27.8 (2.1) 27.9 (2.1) <.01
2† 27.9 (2.1) 27.7 (2.1) 27.9 (2.1) 28.1 (2.1) 27.8 (2.1) 28.1 (2.1) 27.7 (2.0) 28.1 (2.1) 28.3 (2.2) 27.9 (2.1) 27.9 (2.1)
Birth weight, g,
mean (SD)
Total 1064 (264) 1050 (261) 1062 (270) 1065 (266) 1012 (281) 1059 (265) 1054 (270) 1045 (273) 1048 (274) 1047 (262) 1046 (268)
1* 1061 (264) 1048 (259) 1059 (271) 1066 (264) 1012 (280) 1060 (263) 1058 (272) 1048 (272) 1042 (269) 1044 (260) 1045 (267) .05
2† 1069 (265) 1052 (263) 1066 (270) 1065 (269) 1012 (283) 1057 (267) 1050 (269) 1042 (274) 1052 (279) 1050 (263) 1048 (269)
Birth weight z score,
mean (SD)
Total 0.20 (0.96) 0.25 (0.85) 0.38 (0.90) 0.26 (0.79) 0.28 (0.94) 0.32 (0.99) 0.27 (0.85) 0.32 (0.80) 0.18 (0.94) 0.32 (0.92) 0.28 (0.92)
1* 0.19 (0.96) 0.26 (0.85) 0.39 (0.89) 0.27 (0.77) 0.27 (0.94) 0.32 (0.99) 0.26 (0.85) 0.30 (0.81) 0.17 (0.94) 0.31 (0.93) 0.27 (0.92) <.01
2† 0.21 (0.96) 0.25 (0.86) 0.35 (0.92) 0.25 (0.81) 0.30 (0.95) 0.33 (1.00) 0.27 (0.85) 0.36 (0.79) 0.19 (0.94) 0.32 (0.91) 0.29 (0.92)
Males, n (%) Total 11 621 (52.1) 10 914 (52.6) 1345 (51.2) 5195 (51.7) 15 800 (52.1) 9430 (51.7) 2881 (53.9) 2519 (51.5) 740 (50.5) 19 764 (51.9) 80 209 (52.0)
1* 6274 (51.6) 5782 (52.3) 806 (51.7) 2882 (51.7) 8739 (52.6) 5364 (52.2) 1441 (53.4) 1319 (51.2) 341 (50.5) 9059 (51.6) 42 007 (52.0) .87
2† 5347 (52.6) 5132 (52.9) 539 (50.5) 2313 (51.7) 7061 (51.5) 4066 (50.9) 1440 (54.3) 1200 (51.8) 399 (50.5) 10 705 (52.1) 38 202 (52.1)
Multiple births,
n (%)
Total 6648 (29.8) 6136 (29.5) 797 (30.3) 4200 (41.8) 6855 (22.6) 6000 (32.9) 1572 (29.4) 1665 (34.0) 517 (35.4) 10 494 (27.6) 44 884 (29.1)
1* 3705 (30.5) 3361 (30.4) 486 (31.2) 2349 (42.1) 3886 (23.4) 3441 (33.5) 794 (29.4) 879 (34.1) 218 (32.3) 4969 (28.3) 24 088 (29.8) <.01
2† 2943 (28.9) 2775 (28.6) 311 (29.1) 1851 (41.4) 2969 (21.7) 2559 (32.1) 778 (29.3) 786 (33.9) 299 (37.9) 5525 (26.9) 20 796 (28.3)
Cesarean delivery,
n (%)
Total 14 824 (65.4) 13 014 (63.1) 1901 (72.5) 7443 (74.1) 23 724 (79.6) 12 573 (68.9) 3887 (72.8) 4058 (82.9) 1144 (78.1) 21 180 (60.0) 103 448 (68.7)
1* 7832 (64.9) 6874 (62.7) 1142 (73.3) 4090 (73.3) 12 842 (77.9) 6920 (67.4) 1928 (71.4) 2159 (83.8) 519 (76.9) 9258 (58.8) 53 564 (68.1) <.01
2† 6692 (66.0) 6140 (63.4) 759 (71.2) 3353 (75.0) 10 882 (81.8) 5653 (70.8) 1959 (74.1) 1899 (81.9) 625 (79.1) 11 922 (61.0) 49 884 (69.3)
Antenatal steroids,‡
n (%)
Total 20 030 (90.9) 17 805 (88.7) 2482 (95.5) 7893 (78.6) 16 644 (56.8) 15 812 (88.1) 4415 (82.5) 4436 (92.0) 1290 (88.6) 31 868 (88.7) 122 675 (82.1)
1* 10 890 (90.8) 9371 (87.9) 1478 (95.5) 4211 (75.6) 8464 (51.9) 8663 (86.2) 2223 (82.3) 2293 (91.2) 588 (87.9) 13 981 (87.2) 62 162 (79.6) <.01
2† 9140 (91.1) 8434 (89.5) 1004 (95.5) 3682 (82.3) 8180 (63.0) 7149 (90.4) 2192 (82.7) 2143 (92.8) 702 (89.2) 17 887 (89.9) 60 513 (84.6)
Outborn, n (%) Total 2873 (12.9) 3400 (16.4) 134 (5.1) 95 (1.0) 1818 (6.0) 1140 (6.2) 451 (8.5) 238 (4.9) 185 (12.6) NA 10 334 (8.9)
1* 1576 (13.0) 1925 (17.4) 93 (6.0) 56 (1.0) 1117 (6.7) 722 (7.0) 173 (6.4) 122 (4.7) 102 (15.1) NA 5886 (9.3) <.01
2† 1297 (12.8) 1475 (15.2) 41 (3.8) 39 (0.9) 701 (5.1) 418 (5.2) 278 (10.5) 116 (5.0) 83 (10.5) NA 4448 (8.4)
Apgar at 5 min <7,
n (%)
Total 4675 (21.1) 6534 (32.0) 942 (36.9) 1081 (11.0) 8174 (27.6) 2568 (14.4) 1350 (25.7) 1582 (32.5) 225 (15.6) NA 27 131 (23.9)
1* 2591 (21.5) 3368 (30.9) 521 (34.5) 559 (10.4) 4159 (25.6) 1384 (13.8) 626 (23.5) 708 (27.7) 93 (14.1) NA 14 009 (22.6) <.01
2† 2084 (20.7) 3166 (33.2) 421 (40.3) 522 (11.8) 4015 (30.0) 1184 (15.1) 724 (27.9) 874 (37.8) 132 (16.8) NA 13 122 (25.2)
ANZNN, Australia/New Zealand; CNN, Canada; FinMBR, Finland; INN, Israel; NA, not available; NRNJ, Japan; SEN1500, Spain; SNQ, Sweden; SwissNeoNet, Switzerland; Tuscan NN, Tuscany, Italy; UKNC, United Kingdom.
*Epoch 1 is 2007-2011 except United Kingdom (2008-2011) and Tuscany (2009-2011).
†Epoch 2 is 2012-2015.
‡Any antenatal steroids.
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36NICU, or died in the delivery room. Fourth, there are varia-
tions in the definitions of variables and different data collec-
tion mechanisms between countries. However, as we
compared results within each country rather than between
countries, the variable data collection mechanisms should
not be a major limiting factor. Finally, although data from
the entire country/network are requested in iNeo, Japan
(60%) and Spain (50-60%) collected partial population
data and United Kingdom (60%) submitted a partial data
set because only a proportion of neonatal units chose to
participate in iNeo. Despite these limitations, we believe
our interpretation of the results has significant implications
because we did not directly compare data from one country
with another, but instead analyzed the data of each individual
country over time.
One important finding was a reduction in mortality in all
countries except Israel, where it was static (Figure 2 and
Table VI). The Vermont Oxford Network reported a
similar decreased mortality rate for neonates born
between 501 and 1500 g at birth from 13.7% in 2007 to
10.9% in 2014,26 and data from England identified an
increase in survival from 88% to 91.3% between 2008 and
2014 for neonates of 22-32 weeks of gestational age.27 We
identified a significant increase in antenatal steroid use in
epoch 2 that may have contributed to the decrease in
mortality. In addition, of the 9 countries with outborn
rates available, 7 reported a decrease in outborn neonates
in epoch 2, which previous reports showed was associated
with decreased mortality.28-30 However, the observed
practice changes only partly explains the differences in
outcomes rates between and within countries.
Socioeconomic circumstances among countries may differ
and external economic impacts on national scales also
may have contributed to the changes in services available
and outcome changes observed.31
Despite decreasing mortality, there was less improvement
in morbidity (Figures 3-5 and Tables VII-IX). The most
striking finding of our study was that the rate of BPD in
the iNeo collaborative countries increased between epoch 1
and epoch 2, with the exception of Canada (6.9% absolute
reduction) and Finland (1.6% absolute reduction; Figure 5
and Table IX). The lack of improvement in BPD was a
surprise, given the increasing use of gentle respiratory
support care practices, including greater use of noninvasive
ventilation, continuous positive airway pressure, and
availability of different ventilatory modes that are supposed
to be synchronous, patient-friendly, and associated with
less barotrauma.32 The Canadian Neonatal Network
reported concern over static BPD rates between 1996-1997
and 2006-2007 in their participating NICUs. Stoll et al
reported that BPD increased in the US Neonatal Network
Research Center units between 2009 and 2012 for infants at
26 to 27 weeks of gestational age.3 Chen et al reported that
in Switzerland, the rate of BPD was higher during years
2009 to 2012 than during years 2005 to 2008 for infants
born at <32 weeks of gestational age.33 In contrast, Garcia-
Munoz et al from Spain reported that survival withoutLui et al
Figure 1. Trends of composite outcomes (including and excluding BPD) between 2007 and 2015. ANZNN, Australia/New
Zealand;CNN, Canada; FinMBR, Finland; INN, Israel;NRNJ, Japan;SEN1500, Spain;SNQ, Sweden;SwissNeoNet, Switzerland;
Tuscan NN, Tuscany, Italy; UKNC, United Kingdom. The X-axis represents year; Y-axis represents percentage. The P values for
trend were adjusted for birth weight z score, sex, and multiple births. Black lines represent composite outcomes including
mortality or any of the following 3 morbidities: SNI, treated ROP, or BPD. Gray lines represent composite outcomes including
mortality or any of the following 2 morbidities: SNI or treated ROP.
December 2019 ORIGINAL ARTICLESBPD increased from 26.8% between 2002 and 2006 to 32.1%
between 2007 and 2011 for neonates born at 22 to 26 weeks of
gestational age. However, in subsequent analyses, they
reported that the rate of BPD increased in neonates
>27 weeks of gestational age.31,34Trends in Outcomes for Neonates Born Very Preterm and Very LIt is unclear what potentially contributed to our observed
increase in BPD. The first possibility is the definition of
BPD, which is a topic of intense debate.20,22 If the definition
of BPD was consistent within the study period within coun-
try, it should not affect the interpretation of our analyses;ow Birth Weight in 11 High-Income Countries 37
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38however, in database studies like ours, we have no way of
checking the consistency of the BPD definition over time.
Second, it is possible that oxygen saturation targets have
changed as new evidence emerged over the study period,
which may have contributed to the apparent increase in
BPD. Third, it was reported that high use of noninvasive
continuous positive airway pressure leads to increased
time of ventilation and use of supplemental oxygen.35
Fourth, high BPD rates could reflect increased survival of
these neonates. Fifth, we did not adjust data for altitude
of the unit; however, this is unlikely to have changed during
study period. Finally, strategies including postnatal steroids,
vitamin A,36 caffeine,37 avoidance of mechanical ventila-
tion,38 and administration of steroids and surfactant in
combination39 have been associated with reduced BPD,
yet their use in practice is variable.40 For example, during
the study period, the postnatal use of steroids reduced
significantly because of concerns about increased risk of
neurodevelopmental outcomes.41 Vitamin A is not used in
a majority of NICUs because of availability issues and
administration concerns. Caffeine was studied in a large
randomized study during this period. Respiratory manage-
ment, including avoidance of mechanical ventilation, is
practiced widely; however, postextubation management is
variable between both countries and units within coun-
tries.17 Evidence for simultaneous administration of steroid
and surfactant has recently emerged; therefore, the practice
was not in use in any country 2015. Future studies are
needed to determine which management factors are associ-
ated with non-improvement or increases in BPD rates.22
The consistent success of Canada at reducing adverse out-
comes over the study period suggests there may be care prac-
tices that drove this change. One major difference between
Canada and the other countries in iNeo during the study
period was a national program of continuous quality improve-
ment.14,15 In 2008, Canada implemented a national Evidence-
based Practice for Improving Quality-2 initiative in 25 of 30
tertiary NICUs14 that was continued as Evidence-based Prac-
tice for Improving Quality-3 between 2013 and 2017.15 These
programs were associated with a significant reduction in com-
posite outcomes in Canada, and these improvements may be
reflected in the current comparison. However, because the
quality improvement programs were multifaceted and unit-
driven, we were unable to pinpoint specific changes that led
to improvement. These results reinforce the importance of na-
tional networks and registries to be active facilitators of a cul-
ture of continuous quality improvement.42
In conclusion, mortality significantly improved in almost
all countries participating in iNeo; however, the risk of
BPD also increased over the study period in most countries,
except Canada. Within-country comparisons revealed
improvement in the composite outcome including BPD
over years in some countries, but the composite outcome
either remained static or worsened in a majority of iNeo
countries. Our results provide an opportunity for each coun-
try to investigate the reasons for differences in outcome rates
and change over time and work together to harmonizeLui et al
December 2019 ORIGINAL ARTICLESdefinitions, streamline data collection, and identify practice
differences between countries that are associated with
improvement in outcomes. n
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In vitro studies in the mid-1960s suggested that vitamin A had a beneficial effect in cells from patients with muco-polysaccharidosis (MPS) I and II by altering the synthesis and degradation of glycosaminoglycans (GAGs).1
Following this publication, several laboratories tested the hypothesis, alas, arriving at conflicting results. Thus, Madsen
and Linker performed a clinical study to evaluate the effects of vitamin A in patients withMPS I, II, III, and IV. Patients
were treated with the highest nontoxic dose of vitamin A for a period between 4 and 14 months, and they were fol-
lowed up routinely and evaluated biochemically and clinically. This clinical study revealed adverse effects of vitamin A
in patients with MPS I-III contrary to what was suggested by the in vitro studies.1 Among the harmful effects of
vitamin A observed in patients were increased GAGs in urine, hepatosplenomegaly, hyperactivity, and increased fre-
quency of seizures. These effects were reduced after the termination of the vitamin A treatment. Because many phy-
sicians were prescribing long-term treatment with vitamin A,Madsen and Linker advised caution in the interpretation
and translation of in vitro results into the clinic.
Since the publication of these reports, the field of MPS research has grown substantially. Scientists have generated
and characterized animal models for MPS, produced in vitro recombinant enzymes, developed novel treatment stra-
tegies, and gained better insight on the natural history of MPS disorders.
Currently there is enzyme replacement therapy for patients with MPS I, II, IVA, VI, and VII. Enzyme replacement
therapy has shown to decrease GAG storage and ameliorates systemic manifestations of the MPS. However, there are
still challenges that include lack of correction of neurologic manifestations, heart and bone disease, and the high im-
mune response toward the treatment. It is hoped that 50 years later we would be in a time where all these challenges are
solved and other mysteries of this group of diseases are uncovered paving the way for more effective and accessible
treatments for all patients.
Adriana M. Monta~no, PhD
Departments of Pediatrics, and Biochemistry and Molecular Biology
School of Medicine
Saint Louis University
St. Louis, MissouriReference
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Additional members of iNeo Investigators
ANZNN (Australian and New Zealand Neonatal
Network): Kei Lui* Chair of ANZNN. Flinders Medical
Centre, SA: Peter Marshall. Gold Coast University Hospital,
QLD: Peter Schmidt. Blacktown District Hospital, NSW: An-
jali Dhawan*. John Hunter Children’s Hospital, NSW: Paul
Craven, Koert de Waal*. King Edward Memorial and Perth
Children’s Hospitals, WA: Karen Simmer, Andy Gill*, Jane
Pillow*. Liverpool Hospital, NSW: Jacqueline Stack. Mater
Mothers’ Hospital, QLD: Pita Birch, Neonatal Retrieval Ser-
vice, QLD: Lucy Cooke*. Mercy Hospital for Women, VIC:
Dan Casalaz, Jim Holberton*. Monash Medical Centre,
VIC: Alice Stewart. Nepean Hospital, NSW: Lyn Downe.
Newborn Emergency Transport Service (VIC): Michael
Stewart. NSW Pregnancy and Newborn Services Network:
Barbara Bajuk*. NSW Newborn & Paediatric Emergency
Transport Service: Andrew Berry. Royal Children’s Hospital,
VIC: Rod Hunt. Royal Darwin Hospital, NT: Charles Kil-
burn. Royal Hobart Hospital, Tasmania: Tony De Paoli.
Royal Hospital for Women, NSW: Kei Lui*, Srinivas Boli-
setty. Royal North Shore Hospital, NSW: Mary Paradisis.
Royal Prince Alfred Hospital, NSW: Ingrid Rieger. Royal
Brisbane and Women’s Hospital, QLD: Pieter Koorts. Royal
Women’s Hospital, VIC: Carl Kuschel, Lex Doyle. Sydney
Children’s Hospital, NSW: Andrew Numa. The Canberra
Hospital, ACT: Hazel Carlisle. The Children’s Hospital at
Westmead, NSW: Nadia Badawi, Alison Loughran-Fowlds.
The Townsville Hospital, QLD: Guan Koh.Western Australia
Neonatal Transport Service: Jonathan Davis.WestmeadHos-
pital, NSW: Melissa Luig. Women’s & Children’s Hospital,
SA: Chad Andersen*. National Perinatal Epidemiology and
Statistics Unit, University of New South Wales: Georgina
Chambers*. New Zealand: Christchurch Women’s Hospital:
Nicola Austin, Adrienne Lynn. University of Otago, Christ-
church: Brian Darlow. Dunedin Hospital: Liza Edmonds.
Middlemore Hospital: Lindsay Mildenhall. Auckland City
Hospital: Mariam Buksh, Malcolm Battin*. North Shore
and Waitakere Hospitals: Jutta van den Boom*. Waikato
Hospital: David Bourchier. Wellington Women’s Hospital:
Vaughan Richardson, Fiona Dineen*. Singapore: KK
Women’s and Children’s Hospital, Singapore: Victor Samuel
Rajadurai*. Hong Kong: Prince of Wales Hospital: Simon
Lam. United Christian Hospital: Genevieve Fung. (* Denotes
the ANZNN Executive Committee).
CNN (Canadian Neonatal Network): Prakesh S. Shah,
MD, MSc (Director, Canadian Neonatal Network and site
investigator), Mount Sinai Hospital, Toronto, Ontario; Adele
Harrison, MD, MBChB, Victoria General Hospital, Victoria,
British Columbia; Anne Synnes, MDCM, MHSC, and Joseph
Ting, MD, B.C. Women’s Hospital and Health Centre, Van-
couver, British Columbia; Zenon Cieslak, MD, Royal Colum-
bian Hospital, New Westminster, British Columbia; Rebecca
Sherlock, MD, Surrey Memorial Hospital, Surrey, British
Columbia; Wendy Yee, MD, Foothills Medical Centre, Cal-
gary, Alberta; Khalid Aziz, MBBS, MA, MEd, and Jennifer
Toye, MD, Royal Alexandra Hospital, Edmonton, Alberta;
Carlos Fajardo, MD, Alberta Children’s Hospital, Calgary,
Alberta; Zarin Kalapesi, MD, Regina General Hospital, Re-
gina, Saskatchewan; Koravangattu Sankaran, MD, MBBS,
and Sibasis Daspal, MD, Royal University Hospital, Saska-
toon, Saskatchewan; Mary Seshia, MBChB, Winnipeg Health
Sciences Centre, Winnipeg, Manitoba; Ruben Alvaro, MD, St
Boniface General Hospital, Winnipeg, Manitoba; Amit Mu-
kerji, MD, Hamilton Health Sciences Centre, Hamilton, On-
tario; Orlando Da Silva, MD, MSc, London Health Sciences
Centre, London, Ontario; Chuks Nwaesei, MD, Windsor
Regional Hospital, Windsor, Ontario; Kyong-Soon Lee,
MD, MSc, Hospital for Sick Children, Toronto, Ontario;
Michael Dunn, MD, Sunnybrook Health Sciences Centre,
Toronto, Ontario; Brigitte Lemyre, MD, Children’s Hospital
of Eastern Ontario and Ottawa General Hospital, Ottawa,
Ontario; Kimberly Dow, MD, Kingston General Hospital,
Kingston, Ontario; Ermelinda Pelausa, MD, Jewish General
Hospital, Montreal, Quebec; Keith Barrington, MBChB,
Ho^pital Sainte-Justine, Montreal, Quebec; Christine Drolet,
MD, and Bruno Piedboeuf, MD, Centre Hospitalier Univer-
sitaire de Quebec, Sainte Foy Quebec; Martine Claveau, MSc,
LLM, NNP, and Marc Beltempo, MD, McGill University
Health Centre, Montreal, Quebec; Valerie Bertelle, MD,
and Edith Masse, MD, Centre Hospitalier Universitaire de
Sherbrooke, Sherbrooke, Quebec; Roderick Canning, MD,
Moncton Hospital, Moncton, New Brunswick; Hala Makary,
MD, Dr Everett Chalmers Hospital, Fredericton, New Bruns-
wick; Cecil Ojah, MBBS, and Luis Monterrosa, MD, Saint
John Regional Hospital, Saint John, New Brunswick; Akhil
Deshpandey, MBBS, MRCPI, Janeway Children’s Health
and Rehabilitation Centre, St. John’s, Newfoundland; Jehier
Afifi, MB BCh, MSc, IWK Health Centre, Halifax, Nova
Scotia; Andrzej Kajetanowicz, MD, Cape Breton Regional
Hospital, Sydney, Nova Scotia; Shoo K. Lee, MBBS, PhD
(Chairman, Canadian Neonatal Network), Mount Sinai
Hospital, Toronto, Ontario.
FinMBR (Finnish Medical Birth Register): Sture Ander-
sson, MD, Helsinki University Hospital, Helsinki; Liisa Leh-
tonen, MD, Turku University Hospital, Turku; Outi
Tammela, MD, Tampere University Hospital, Tampere;
Ulla Sankilampi, MD, Kuopio University Hospital, Kuopio;
Timo Saarela, MD, Oulu University Hospital, Oulu.
ILL (Illinois Neonatal Network): Preetha Prazad, MD,
Advocate Children’s Hospital, Park Ridge, Illinois; Akihiko
Noguchi, MD, SSM Cardinal Glennon/St Mary’s Hospital,
St Louis Missouri; Kamlesh McWan, MD, Children’s Hospi-
tal of Illinois, Peoria, Illinois; Beau Button, MD, St John’s
Hospital, Springfield, Illinois; William Stratton, MD, Carle
Foundation Hospital, Urbana, Illinois; Aaron Hamvus,
MD, Northwestern University Hospitals, Chicago, Illinois;
Aarti Raghaven, MD, University Illinois Chicago Hospital,
Chicago, Illinois; Matthew Derrick, MD, Evanston North-
shore Hospital, Evanston, Illinois; Radley Hadley, MD,
Advocate Illinois Masonic Hospital, Chicago, Illinois; Robert
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Covert, MD, Edward Hospital, Naperville, Illinois; Omar
Lablanc, MD, John H. Stroger Cook County Hospital, Chi-
cago, Illinois; Marc Weiss, MD, RMCH Loyola University
Hospital, Maywood, Illinois; Anthony Bell, MD, Adventist
Hinsdale Hospital, Hinsdale, Illinois; Maliha Shareef, MD,
St Alexius Hospital, Hoffman Estates, Illinois; Jean Silvestri,
MD, Rush University Hospital, Chicago, Illinois.
INN (Israel Neonatal Network): Eli Heymann, MD, Assaf
Harofeh Medical Center, Tzrifin; Shmuel Zangen, MD,
Barzilai Medical Center, Ashkelon; Tatyana Smolkin, MD,
Baruch Padeh Medical Center, Poriya; Francis Mimouni,
MD, Bikur Cholim Hospital, Jerusalem; David Bader, MD,
Bnai Zion Medical Center, Haifa; Avi Rothschild, MD,
Carmel Medical Center, Haifa; Zipora Strauss, Chaim Sheba
Medical Center, Ramat Gan; Clari Felszer, MD, Emek
Medical Center, Afula; Hussam Omari, MD, French Saint
Vincent de Paul Hospital, Nazareth; Smadar Even Tov-
Friedman, MD, Hadassah University Hospital-Ein Karem,
Jerusalem; Benjamin Bar-Oz, MD, Hadassah University
Hospital-Har Hazofim, Jerusalem; Michael Feldman, MD,
Hillel Yaffe Medical Center, Hadera; Nizar Saad, MD, Holy
Family (Italian) Hospital, Nazareth; Orna Flidel-Rimon,
MD, Kaplan Medical Center, Rehovot; Meir Weisbrod,
MD, LaniadoHospital, Netanya; Daniel Lubin,MD,Mayanei
Hayeshua Medical Center, Bnei Brak; Ita Litmanovitz, MD,
Meir Medical Center, Kfar Saba; Amir Kugelman, MD, Ram-
bam Medical Center; Eric Shinwell, MD, Rivka Ziv Medical
Center, Safed; Gil Klinger, MD, Schneider Children’sMedical
Center of Israel, Rabin Medical Center (Beilinson Campus),
Petah Tikva; Yousif Nijim, MD, Scottish (EMMS) Hospital,
Nazareth; Alona Bin-Nun, MD, Shaare-Zedek Medical Cen-
ter, Jerusalem; Agneta Golan, MD, Soroka Medical Center,
Beersheba; Dror Mandel, MD, Sourasky Medical Center,
Tel Aviv; Vered Fleisher-Sheffer, MD, Western Galilee Med-
ical Center, Nahariya; David Kohelet, MD, Wolfson Medical
Center, Holon; Lev Bakhrakh, MD, Yoseftal Hospital, Eilat.
NRNJ (Neonatal Research Network Japan): Satoshi Hat-
tori, MD, Sapporo City Hospital, Sapporo, Hokkaido; Ma-
saru Shirai, MD, Asahikawa Kosei Hospital, Asahikawa,
Hokkaido; Toru Ishioka, MD, Engaru Kosei Hospital, En-
garu, Hokkaido; Toshihiko Mori, MD, NTT East Sappro
Hospital, Sapporo, Hokkaido; Takasuke Amizuka, MD, Ao-
mori Prefecture Central Hospital, Aomori, Aomori; Toru
Huchimukai, MD, Iwate Prefecture Ohfunato Hospital,
Ofunato, Iwate; Hiroshi Yoshida, MD, Tsuruoka City Sho-
nai Hospital, Tsuruoka, Yamagata; Ayako Sasaki, MD, Ya-
magata University, Yamagata, Yamagata; Junichi Shimizu,
MD, Tsuchiura Kyodo Hospital, Tsuchiura, Ibaraki; Toshi-
hiko Nakamura, MD, National Nishisaitama Central Hospi-
tal, Tokorozawa, Saitama; Mami Maruyama, MD, Jichi
Medical University Saitame Medical Center, Omiya, Sai-
tama; Hiroshi Matsumoto, MD, Asahi Central Hospital,
Asahi, Chiba; Shinichi Hosokawa, MD, National Interna-
tional Medical Center, Shinjuku, Tokyo; Atsuko Taki,
MD, Tokyo Medical and Dental University, Bunkyo, Tokyo;
Machiko Nakagawa, MD, Saint Luku Hospital, Chuo, To-
kyo; Kyone Ko, MD, Sanikukai Hospital, Sumida, Tokyo;
Azusa Uozumi, MD, Odawara City Hospital, Odawara, Ka-
nagawa; Setsuko Nakata, MD, Iida City Hospital, Iida, Na-
gano; Akira Shimazaki, MD, National Shinshu Ueda
Medical Center, Ueda, Nagano; Tatsuya Yoda, MD, Saku
General Hospital, Saku, Nagano; Osamu Numata, MD, Na-
gaoka Red Cross Hospital, Nagaoka, Niigata; Hiroaki Ima-
mura, MD, Koseiren Takaoka Hospital, Takaoka, Toyama;
Azusa Kobayashi, MD, KanazawaMedical University, Kana-
zawa, Kanazawa; Shuko Tokuriki, MD, Fukui University,
Fukui, Fukui; Yasushi Uchida, MD, National Nagara Medi-
cal Center, Nagara, Gifu; Takahiro Arai, MD, Takayama Red
Cross Hospital, Takayama, Gifu; Mitsuhiro Ito, MD, Fu-
jieda City Hospital, Fujieda, Shizuoka; Kuniko Ieda, MD,
Koritsu Tosei Hospital, Toyota, Aichi; Toshiyuki Ono,
MD, Komaki City Hospital, Komaki, Aichi; Masashi Haya-
shi, MD, Okazaki City Hospital, Okazaki, Aichi; Kanemasa
Maki, MD, Yokkaichi City Hospital, Yokkaichi, MieToru
Yamakawa, MD, Japan Baptist Hospital, Kyoto, Kyoto; Ma-
sahiko Kawai, MD, Kyoto University, Kyoto, Kyoto; Noriko
Fujii, MD, Fukuchiyama City Hospital, Fukuchiyama,
Kyoto; Kozue Shiomi, MD, Kyoto City Hospital, Kyoto,
Kyoto; Koji Nozaki, MD, Mitubishi Kyoto Hospital, Kyoto,
Kyoto; Hiroshi Wada, MD, Yodogawa Christian Hospital,
Osaka, Osaka; Taho Kim, MD, Osaka City Sumiyoshi Hos-
pital, Osaka, Osaka; Yasuyuki Tokunaga, MD, Toyonaka
City Hospital, Toyonaka, Osaka; Yasuyuki Tokunaga, MD,
National Cerebral and Cardiovascular Center, Suita, Osaka;
Akihiro Takatera, MD, Chifune Hospital, Osaka, Osaka;
Toshio Oshima, MD, Bell Land General Hospital, Sakai,
Osaka; Hiroshi Sumida, MD, Rinku General Hospital, Izu-
misano, Osaka; Yae Michinomae, MD, Yao City Hospital,
Yao, Osaka; Yoshio Kusumoto, MD, Osaka General Medical
Center, Osaka, Osaka; Seiji Yoshimoto, MD, Kobe Chil-
dren’s Hospital, Kobe, Hyogo; Takeshi Morisawa, MD, Ka-
kogawa City Hospital, Kakogawa, Hyogo; Tamaki Ohashi,
MD, Hyogo Prefectural Awaji Hospital, Sumoto, Hyogo;
Yukihiro Takahashi, MD, Nara Prefecture Medical Univer-
sity, Kashiwara, Nara; Moriharu Sugimoto, MD, Tsuyama
Central Hospital, Tsuyama, Okayama; Noriaki Ono, MD,
Hiroshima University, Hiroshima, Hiroshima; Shinichiro
Miyagawa, MD, National Kure Medical Center, Kure, Hir-
oshima; Takahiko Saijo, MD, Tokushima University, To-
kushima, Tokushima; Takashi Yamagami, MD,
Tokushima City Hospital, Tokushima, Tokushima; Kosuke
Koyano, MD, Kagawa University, Kida, Kagawa; Shoko Ko-
bayashi, MD, Shikoku Medical Center for Children and
Adults, Zentsuji, Kagawa; Takeshi Kanda, MD, National
Kyushu Medical Center, Fukuoka, Fukuoka; Yoshihiro
Sakemi, MD, National Kokura Medical Center, Kitakyushu,
Fukuoka; Mikio Aoki, MD, National Nagasaki Medical Cen-
ter, Nagasaki, Nagasaki; Koichi Iida, MD, Oita Prefectural
Hospital, Oita, Oita; Mitsushi Goshi, MD, Nakatsu City
Hospital, Nakatsu, Oita; Yuko Maruyama, MD, Imakyure
General Hospital, Kagoshima, Kagoshima.
SEN1500 (Spanish Neonatal Network): Alejandro Avila-
Alvarez, MD, and Jose Luis Fernandez-Trisac, MD, Com-
plexo Hospitalario Universitario De A Coru~na, A Coru~na;
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Ma Luz Couce Pico, MD, and Marıa Jose Fernandez Seara,
MD, Hospital Clınico Universitario de Santiago, Santiago
de Compostela; Andres Martınez Gutierrez, MD, Complejo
Hospitalario Albacete, Albacete; Carolina Vizcaıno, MD,
Hospital General Universitario de Elche, Alicante; Miriam
Salvador Iglesias, MD, and Honorio Sanchez Zaplana, MD,
Hospital General Universitario de Alicante, Alicante; Belen
Fernandez Colomer, MD, and Jose Enrique Garcıa Lopez,
MD, Hospital Universitario Central de Asturias, Oviedo, As-
turias; Rafael Garcıa Mozo, MD, and M. Teresa Gonzalez
Martınez, MD, Hospital Universitario de Cabue~nes, Gijon,
Asturias; Ma Dolores Muro Sebastian, MD, and Marta Balart
Carbonell, MD, Clınica Corachan, Barcelona; Joan Badia
Barnusell, MD, andMonica Domingo Puiggros, MD, Corpo-
racio Parc Taulı, Sabadell, Barcelona; Josep Figueras Aloy,
MD, and Francesc Botet Mussons, MD, Hospital Clınic de
Barcelona, Barcelona; Israel Anquela Sanz, MD, Hospitalario
De Granollers, Granollers; Gemma Ginovart Galiana, MD,
H. De La Santa Creu I Sant Pau, Barcelona; W. Coroleu,
MD, Hospital Universitari Germans Trias I Pujol, Badalona;
Martin Iriondo, MD, Hospital Sant Joan de Deu Barcelona,
Esplugues de Llobregat, Barcelona; Laura Castells Vilella,
MD, Hospital General de Catalu~na, Barcelona; Roser Porta,
MD, Institute Dexeus, Barcelona; Xavier Demestre, MD,
and Silvia Martınez Nadal, MD, Scias-Hospital Barcelona,
Barcelona; Cristina de Frutos Martınez, MD, Hospital Uni-
versitario de Burgos, Burgos; Marıa Jesus Lopez Cuesta,
MD, H. San Pedro de Alcantara, Caceres; Dolores Esquivel
Mora, MD, and Joaquın Ortiz Tardıo, MD, Hospital Jerez,
Cadiz; Isabel Benavente, MD, and Almudena Alonso, MD,
Hospital Universitario Puerta Del Mar, Cadiz; Ramon Agui-
lera Olmos, MD, Hospital General de Castellon, Castellon;
Miguel A. Garcıa Cabezas, MD, and Ma Dolores Martınez
Jimenez, MD, Hospital General Universitario de Ciudad
Real, Ciudad Real; Ma Pilar Jaraba Caballero, MD, and Ma
Dolores Ordo~nez Dıaz, MD, Hospital Universitario Reina
Sofıa, Cordoba; Alberto Trujillo Fagundo, MD, and Lluis
Mayol Canals, MD, Hospital Universitari de Girona Dr. Jo-
sep Trueta, Girona; Fermın Garcıa-Mu~noz Rodrigo, MD,
and Lourdes Urquıa Martı, MD, H.M.I. Las Palmas, Las Pal-
mas, Gran Canaria; Marıa FernandaMoreno Galdo, MD, and
Jose Antonio Hurtado Suazo, MD, Hospital Universitario
Virgen De Las Nieves, Granada; Eduardo Narbona Lopez,
and Jose Uberos Fernandez, MD, Hospital Universitario
San Cecilio, Granada; Miguel A. Cortajarena Altuna, MD,
and Oihana Muga Zuriarrain Hospital, MD, Donostia, Gi-
puzkoa; David Mora Navarro, MD, Hospital Juan Ramon
Jimenez, Huelva; Marıa Teresa Domınguez, MD, Hospital
Costa De La Luz, Huelva; Ma Yolanda Ruiz del Prado, MD,
and Ines Esteban Dıez, MD, Hospital San Pedro, Logro~no,
La Rioja; Marıa Teresa Palau Benavides, MD, and Santiago
Lape~na, MD, Hospital de Leon, Leon, Leon; Teresa Prada,
MD, Hospital del Bierzo, Ponferrada, Leon; Eduard Soler
Mir, MD, Hospital Arnau De Vilanova, Lleida; Araceli Cor-
redera Sanchez, MD, Enrique Criado Vega, MD, Nayade
del Prado, MD, and Cristina Fernandez, MD, Hospital
Clınico San Carlos, Madrid; Lucıa Cabanillas Vilaplana,
MD, and Irene Cuadrado Perez, MD, Hospital Universitario
De Getafe, Madrid; Luisa Lopez Gomez, MD, Hospital De La
Zarzuela, Madrid; Laura Domingo Comeche, MD, Hospital
Universitario de Fuenlabrada, Fuenlabrada, Madrid; Isabel
Llana Martın, MD, Hospital Madrid-Torrelodones, Madrid,
Madrid; Carmen Gonzalez Armengod, MD, and Carmen
Mu~noz Labian, MD, Hospital Universitario Puerta De Hi-
erro, Majadahonda, Madrid; Ma Jose Santos Mu~noz, MD,
Hospital Severo Ochoa, Leganes, Madrid; Dorotea Blanco
Bravo, MD, and Vicente Perez, MD, Hospital Gregorio
Mara~non, Madrid; Ma Dolores Elorza Fernandez, MD, Celia
Dıaz Gonzalez, MD, and Susana Ares Segura, MD, H.U. La
Paz, Madrid; Manuela Lopez Azorın, MD, Hospital Univer-
sitario Quironsalud Madrid, Madrid; Ana Belen Jimenez
MD, Hospital Universitario Fundacion Jimenez Dıaz, Ma-
drid; Tomas Sanchez-Tamayo, MD, and Elıas Tapia Moreno,
MD, Hospital Carlos Haya, Malaga; Marıa Gonzalez, MD,
and Jose Enrique Sanchez Martınez, MD, Hospital Parque
San Antonio De Malaga, Malaga; Jose Marıa Lloreda Garcıa,
MD, Hospital Universitario Santa Lucia De Cartagena, Mur-
cia; Concepcion Go~ni Orayen, MD, Hospital Virgen Del Ca-
mino De Pamplona, Pamplona, Navarra; Javier Vilas
Gonzalez, MD, Complexo Hospitalario Pontevedra, Ponte-
vedra; Marıa Suarez Albo, MD, and Eva Gonzalez Colme-
nero, MD, Hospital Xeral De Vigo, Pontevedra; Elena Pilar
Gutierrez Gonzalez, MD, and Beatriz Vacas del Arco, MD,
Hospital Universitario de Salamanca, Salamanca; Josefina
Marquez Fernandez, MD, and Laura Acosta Gordillo, MD,
Hospital Valme, Sevilla; Mercedes Granero Asensio, MD,
Hospital Virgen De La Macarena, Sevilla; Carmen Macıas
Dıaz, MD, Hospital Universitario Virgen Del Rocıo, Sevilla;
Mar Albujar, MD, Hospital Universitari de Tarragona Joan
XXIII, Tarragona; Pedro Fuster Jorge. MD, Hospital Univer-
sitario De Canarias, San Cristobal de La Laguna, Santa Cruz
de Tenerife; Sabina Romero, MD, and Monica Rivero Falero,
MD, Hospital Universitario Nuestra Se~nora De Candelaria,
Santa Cruz de Tenerife; Ana Belen Escobar Izquierdo, Hospi-
tal Virgen De La Salud, Toledo; Javier Esta~n Capell, MD,
Hospital Clinico Universitario De Valencia, Valencia; Ma Isa-
bel Izquierdo Macian, MD, Hospital Universitari La Fe, Va-
lencia; Ma Mar Montejo Vicente, MD, and Raquel Izquierdo
Caballero, MD, Hospital Universitario Rıo Hortega, Valla-
dolid; Ma Mercedes Martınez, MD, and Aintzane Euba,
MD, Hospital de Txagorritxu, Vitoria-Gasteiz; Amaya
Rodrıguez Serna, MD, and Juan Marıa Lopez de Heredia
Goya, MD, Hospital de Cruces, Baracaldo; Alberto Perez Le-
gorburu, MD, and Ana Gutierrez Amoros, MD, Hospital
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Figure 2. Trends of mortality between 2007 and 2015.
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Figure 3. Trends of SNI between 2007 and 2015.
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Figure 4. Trends of treated ROP between 2007 and 2015.
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Figure 5. Trends of BPD between 2007 and 2015.
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Figure 6. Standardized ratios* of composite outcomes for Epoch 1† and Epoch 2‡. *Adjusted for gestational age, birth weight z
score, sex, and multiple births. †Epoch 1 is 2007-2011 except for UKNC (2008-2011) and TuscanNN (2009-2011). ‡Epoch 2 is
2012- 2015.
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Table III. Distribution of gestational age over study years
Gestational age
2007
N = 11 669
2008
N = 16 039
2009
N = 16 650
2010
N = 17 845
2011
N = 18 603
2012
N = 19 149
2013
N = 18 403
2014
N = 18 229
2015
N = 17 646
Total
N = 15 233
24 wk, n (%) 849 (7.3) 1169 (7.3) 1199 (7.2) 1277 (7.2) 1364 (7.3) 1371 (7.2) 1375 (7.5) 1375 (7.5) 1323 (7.5) 11 302 (7.3)
25 wk, n (%) 1120 (9.6) 1561 (9.7) 1519 (9.1) 1631 (9.1) 1707 (9.2) 1798 (9.4) 1682 (9.1) 1662 (9.1) 1615 (9.2) 14 295 (9.3)
26 wk, n (%) 1405 (12.0) 1847 (11.5) 1931 (11.6) 2150 (12.0) 2143 (11.5) 2104 (11.0) 2065 (11.2) 2020 (11.1) 1964 (11.1) 17 629 (11.4)
27 wk, n (%) 1531 (13.1) 2208 (13.8) 2255 (13.5) 2414 (13.5) 2473 (13.3) 2555 (13.3) 2421 (13.2) 2367 (13) 2265 (12.8) 20 489 (13.3)
28 wk, n (%) 1828 (15.7) 2588 (16.1) 2607 (15.7) 2765 (15.5) 3008 (16.2) 3100 (16.2) 2871 (15.6) 2899 (15.9) 2826 (16.0) 24 492 (15.9)
29 wk, n (%) 1846 (15.8) 2630 (16.4) 2749 (16.5) 2948 (16.5) 3086 (16.6) 3156 (16.5) 3043 (16.5) 2955 (16.2) 2881 (16.3) 25 294 (16.4)
30 wk, n (%) 1753 (15.0) 2330 (14.5) 2496 (15.0) 2622 (14.7) 2689 (14.5) 2910 (15.2) 2787 (15.1) 2804 (15.4) 2740 (15.5) 23 131 (15.0)
31 wk, n (%) 1337 (11.5) 1706 (10.6) 1894 (11.4) 2038 (11.4) 2133 (11.5) 2155 (11.3) 2159 (11.7) 2147 (11.8) 2032 (11.5) 17 601 (11.4)
Table II. Population gestational age distribution
Gestational
age
ANZN
N = 22 331
CNN
N = 20 783
FINMBR
N = 2627
INN
N = 10 050
NRNJ
N = 30 343
SEN1500
N = 18 257
SNQ
N = 5351
SwissNeoNet
N = 4895
Tuscan NN
N = 1465
UKNC
N = 38 131
Total
N = 154 233
24 wk, n (%) 1552 (6.9) 1531 (7.4) 180 (6.9) 652 (6.5) 2567 (8.5) 1072 (5.9) 397 (7.4) 262 (5.4) 118 (8.1) 2971 (7.8) 11 302 (7.3)
25 wk, n (%) 2081 (9.3) 2233 (10.7) 232 (8.8) 798 (7.9) 2921 (9.6) 1553 (8.5) 525 (9.8) 419 (8.6) 106 (7.2) 3427 (9.0) 14 295 (9.3)
26 wk, n (%) 2643 (11.8) 2533 (12.2) 267 (10.2) 1064 (10.6) 3494 (11.5) 1961 (10.7) 656 (12.3) 572 (11.7) 117 (8.0) 4322 (11.3) 17 629 (11.4)
27 wk, n (%) 2918 (13.1) 2928 (14.1) 396 (15.1) 1219 (12.1) 3987 (13.1) 2333 (12.8) 760 (14.2) 630 (12.9) 167 (11.4) 5151 (13.5) 20 489 (13.3)
28 wk, n (%) 3754 (16.8) 3368 (16.2) 421 (16.0) 1464 (14.6) 4593 (15.1) 2754 (15.1) 893 (16.7) 742 (15.2) 191 (13.0) 6312 (16.6) 24 492 (15.9)
29 wk, n (%) 3707 (16.6) 3389 (16.3) 422 (16.1) 1663 (16.5) 4741 (15.6) 3078 (16.9) 892 (16.7) 850 (17.4) 235 (16.0) 6317 (16.6) 25 294 (16.4)
30 wk, n (%) 3290 (14.7) 2866 (13.8) 416 (15.8) 1697 (16.9) 4613 (15.2) 3037 (16.6) 712 (13.3) 788 (16.1) 287 (19.6) 5425 (14.2) 23 131 (15.0)
31 wk, n (%) 2386 (10.7) 1935 (9.3) 293 (11.2) 1493 (14.9) 3427 (11.3) 2469 (13.5) 516 (9.6) 632 (12.9) 244 (16.7) 4206 (11.0) 17 601 (11.4)
Total 22 331 20 783 2627 10 050 30 343 18 257 5351 4895 1465 38 131 154 233
ANZN, Australian and New Zealand Neonatal Network; CNN, Canadian Neonatal Network; FINMBR, Finnish Medical Birth Register; INN, Israel Neonatal Network; NRNJ, Neonatal Research Network Japan; SEN1500, Spanish Neonatal Network; SNQ, Swedish Neonatal
Quality Register; SwissNeoNet, Swiss Neonatal Network; Tuscan NN, Tuscany Neonatal Network; UKNC, United Kingdom Neonatal Collaborative.
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Table V. Annual composite outcome rates between 2007 and 2015 for countries participating in iNeo
Countries Outcome 2007 N = 11 669 2008 N = 16 039 2009 N = 16 650 2010 N = 17 845 2011 N = 18 603 2012 N = 19 149 2013 N = 18 403 2014 N = 18 229 2015 N = 17 646 P trend*
ANZNN Composite† 773/2351 (32.9) 809/2425 (33.4) 792/2337 (33.9) 822/2176 (37.8) 938/2413 (38.9) 949/2512 (37.8) 947/2416 (39.2) 1022/2446 (41.8) 999/2333 (42.8) <.01 (i)
Composite‡ 359/2447 (14.7) 389/2539 (15.3) 360/2426 (14.8) 353/2248 (15.7) 375/2501 (15.0) 356/2607 (13.7) 322/2539 (12.7) 370/2573 (14.4) 304/2451 (12.4) <.01 (d)
CNN Composite† 735/1626 (45.2) 820/1943 (42.2) 849/2005 (42.3) 758/2093 (36.2) 722/2078 (34.7) 703/2233 (31.5) 697/2205 (31.6) 712/2226 (32.0) 619/2111 (29.3) <.01 (d)
Composite‡ 395/1849 (21.4) 446/2200 (20.3) 466/2260 (20.6) 440/2453 (17.9) 421/2306 (18.3) 428/2472 (17.3) 423/2460 (17.2) 436/2478 (17.6) 342/2305 (14.8) <.01 (d)
FinMBR Composite† 109/278 (39.2) 94/274 (34.3) 113/284 (39.8) 86/287 (30.0) 112/303 (37.0) 76/259 (29.3) 67/224 (29.9) 72/254 (28.3) 99/259 (38.2) .08 (d)
Composite‡ 67/311 (21.5) 51/311 (16.4) 76/304 (25.0) 49/306 (16.0) 60/328 (18.3) 35/268 (13.1) 36/249 (14.5) 42/278 (15.1) 48/272 (17.6) .01 (d)
INN Composite† 349/1034 (33.8) 358/1101 (32.5) 384/1161 (33.1) 371/1102 (33.7) 318/1080 (29.4) 385/1145 (33.6) 339/1026 (33.0) 339/1096 (30.9) 335/1155 (29.0) .03 (d)
Composite‡ 272/1044 (26.1) 268/1126 (23.8) 293/1188 (24.7) 291/1123 (25.9) 235/1096 (21.4) 303/1163 (26.1) 246/1050 (23.4) 253/1103 (22.9) 219/1157 (18.9) <.01 (d)
NRNJ Composite† 1143/3024 (37.8) 1011/2945 (34.3) 1108/3078 (36.0) 1362/3562 (38.2) 1321/3694 (35.8) 1379/3746 (36.8) 1376/3468 (39.7) 1289/3111 (41.4) 1013/2533 (40.0) <.01 (i)
Composite‡ 873/3025 (28.9) 718/2949 (24.3) 747/3082 (24.2) 884/3692 (23.9) 790/3885 (20.3) 849/3936 (21.6) 728/3654 (19.9) 634/3325 (19.1) 509/2795 (18.2) <.01 (d)
SEN1500 Composite† 743/1925 (38.6) 750/2065 (36.3) 809/2056 (39.3) 675/1799 (37.5) 739/1889 (39.1) 741/1947 (38.1) 705/1833 (38.5) 799/1831 (43.6) 719/1781 (40.4) <.01 (i)
Composite‡ 592/1983 (29.9) 596/2150 (27.7) 608/2211 (27.5) 519/1910 (27.2) 558/2019 (27.6) 543/2108 (25.8) 517/1956 (26.4) 623/2015 (30.9) 574/1905 (30.1) .34
SNQ Composite† 153/537 (28.5) 170/552 (30.8) 163/523 (31.2) 183/575 (31.8) 162/459 (35.3) 214/569 (37.6) 209/617 (33.9) 254/618 (41.1) 273/656 (41.6) <.01 (i)
Composite‡ 85/537 (15.8) 91/554 (16.4) 88/523 (16.8) 105/575 (18.3) 87/511 (17.0) 97/612 (15.8) 98/669 (14.6) 110/659 (16.7) 115/711 (16.2) .69
SwissNeoNet Composite† 114/466 (24.5) 128/509 (25.1) 136/502 (27.1) 156/536 (29.1) 132/538 (24.5) 161/580 (27.8) 135/526 (25.7) 152/562 (27.0) 158/629 (25.1) .97
Composite‡ 83/473 (17.5) 84/516 (16.3) 82/507 (16.2) 103/541 (19.0) 82/538 (15.2) 79/581 (13.6) 74/529 (14.0) 83/569 (14.6) 90/641 (14.0) .01 (d)
TuscanNN Composite† NA NA 90/258 (34.9) 54/228 (23.7) 53/187 (28.3) 57/201 (28.4) 62/203 (30.5) 54/177 (30.5) 49/205 (23.9) .18
Composite‡ NA NA 76/259 (29.3) 44/229 (19.2) 40/187 (21.4) 40/202 (19.8) 44/203 (21.7) 46/179 (25.7) 38/206 (18.4) .10
UKNC Composite† NA 1543/3683 (41.9) 1620/3882 (41.7) 2116/4764 (44.4) 2428/5231 (46.4) 2462/5200 (47.3) 2406/5092 (47.3) 2439/5050 (48.3) 2400/5202 (46.1) <.01 (i)
Composite‡ NA 665/3694 (18.0) 664/3890 (17.1) 895/4768 (18.8) 1012/5232 (19.3) 1000/5200 (19.2) 975/5094 (19.1) 954/5050 (18.9) 937/5203 (18.0) .28
*The P trend was adjusted for birth weight z score, sex, and multiple births; (i) denote increasing trend and (d) denote decreasing trend.
†Composite outcome included mortality or any of the following 3 morbidities: SNI, treated ROP, or BPD.
‡Composite outcome included mortality or any of the following 2 morbidities: SNI or treated ROP.
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Table VII. SNI rates between 2007 and 2015 in countries participating in iNEO
Countries/regions 2007 2008 2009 2010 2011 2012 2013 2014 2015 P trend*
ANZNN, n/N (%) 163/2355 (6.9) 161/2405 (6.7) 168/2308 (7.3) 153/2142 (7.1) 156/2377 (6.6) 150/2453 (6.1) 146/2394 (6.1) 149/2400 (6.2) 147/2299 (6.4) .08
CNN, n/N (%) 184/1594 (11.5) 232/1912 (12.1) 246/1961 (12.5) 225/2297 (9.8) 199/2178 (9.1) 248/2314 (10.7) 230/2278 (10.1) 231/2293 (10.1) 223/2168 (10.3) .01
FinMBR, n/N (%) 33/311 (10.6) 28/311 (9.0) 34/304 (11.2) 25/306 (8.2) 35/328 (10.7) 14/268 (5.2) 20/249 (8.0) 22/278 (7.9) 26/272 (9.6) .20
INN, n/N (%) 154/1008 (15.3) 151/1076 (14.0) 159/1121 (14.2) 185/1075 (17.2) 130/1056 (12.3) 175/1106 (15.8) 136/989 (13.8) 152/1074 (14.2) 115/1128 (10.2) .01
NRNJ, n/N (%) 237/3019 (7.9) 234/2940 (8.0) 207/3074 (6.7) 285/3602 (7.9) 261/3801 (6.9) 238/3775 (6.3) 227/3486 (6.5) 199/3102 (6.4) 164/2546 (6.4) <.01
SEN1500, n/N (%) 272/1896 (14.3) 296/2014 (14.7) 306/1989 (15.4) 279/1767 (15.8) 270/1852 (14.6) 322/1884 (17.1) 291/1780 (16.3) 316/1793 (17.6) 283/1747 (16.2) <.01
SNQ, n/N (%) 29/537 (5.4) 36/552 (6.5) 34/523 (6.5) 56/575 (9.7) 31/439 (7.1) 39/550 (7.1) 45/597 (7.5) 52/601 (8.7) 55/636 (8.6) .03
SwissNeoNet, n/N (%) 57/468 (12.2) 37/513 (7.2) 46/504 (9.1) 47/534 (8.8) 45/538 (8.4) 42/579 (7.3) 37/528 (7.0) 43/566 (7.6) 52/638 (8.2) .04
TuscanNN, n/N (%) NA NA 56/256 (21.9) 26/223 (11.7) 13/182 (7.1) 25/199 (12.6) 24/200 (12.0) 24/174 (13.8) 18/201 (9.0) .54
UKNC, n/N (%) NA 275/3694 (7.4) 234/3890 (6.0) 363/4768 (7.6) 428/5232 (8.2) 454/5200 (8.7) 405/5094 (8.0) 423/5050 (8.4) 399/5203 (7.7) .01
*The P trend was adjusted for birth weight z score, sex, and multiple births.
Table VI. Mortality rates between 2007 and 2015 in countries participating in iNEO
Countries/regions 2007 N = 11 669 2008 N = 16 039 2009 N = 16 650 2010 N = 17 845 2011 N = 18 603 2012 N = 19 149 2013 N = 18 403 2014 N = 18 229 2015 N = 17 646 P trend*
ANZNN, n/N (%) 181/2447 (7.4) 226/2539 (8.9) 194/2426 (8.0) 219/2248 (9.7) 228/2501 (9.1) 196/2607 (7.5) 179/2539 (7.1) 205/2573 (8.0) 169/2451 (6.9) .04
CNN, n/N (%) 193/1849 (10.4) 211/2200 (9.6) 238/2260 (10.5) 194/2453 (7.9) 213/2306 (9.2) 210/2472 (8.5) 214/2460 (8.7) 190/2478 (7.7) 153/2305 (6.6) <.01
FinMBR, n/N (%) 37/311 (11.9) 28/311 (9.0) 35/304 (11.5) 23/306 (7.5) 20/328 (6.1) 12/268 (4.5) 11/249 (4.4) 18/278 (6.5) 22/272 (8.1) .06
INN, n/N (%) 136/1044 (13.0) 148/1126 (13.1) 181/1188 (15.2) 157/1123 (14.0) 132/1096 (12.0) 176/1163 (15.1) 155/1050 (14.8) 134/1103 (12.1) 142/1157 (12.3) .42
NRNJ, n/N (%) 174/3025 (5.8) 180/2949 (6.1) 138/3082 (4.5) 163/3692 (4.4) 144/3885 (3.7) 138/3936 (3.5) 118/3654 (3.2) 134/3325 (4.0) 77/2795 (2.8) <.01
SEN1500, n/N (%) 366/1983 (18.5) 377/2150 (17.5) 372/2211 (16.8) 283/1910 (14.8) 350/2019 (17.3) 289/2108 (13.7) 253/1956 (12.9) 249/2015 (12.4) 244/1905 (12.8) <.01
SNQ, n/N (%) 40/537 (7.4) 45/554 (8.1) 39/523 (7.5) 43/575 (7.5) 47/511 (9.2) 54/612 (8.8) 53/669 (7.9) 52/659 (7.9) 42/711 (5.9) .48
SwissNeoNet, n/N (%) 43/473 (9.1) 54/516 (10.5) 50/507 (9.9) 61/541 (11.3) 50/538 (9.3) 48/581 (8.3) 48/529 (9.1) 55/569 (9.7) 55/641 (8.6) .32
TuscanNN, n/N (%) NA NA 32/259 (12.4) 25/229 (10.9) 26/187 (13.9) 19/202 (9.4) 22/203 (10.8) 21/179 (11.7) 22/206 (10.7) .57
UKNC, n/N (%) NA 420/3694 (11.4) 405/3890 (10.4) 493/4768 (10.3) 572/5232 (10.9) 542/5200 (10.4) 471/5094 (9.2) 421/5050 (8.3) 411/5203 (7.9) <.01
*The P trend was adjusted for birth weight z score, sex, and multiple births.
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Table IX. BPD rates between 2007 and 2015 in countries participating in iNEO
Countries/regions 2007 2008 2009 2010 2011 2012 2013 2014 2015 P trend*
ANZNN, n/N (%) 518/2253 (23.0) 515/2301 (22.4) 512/2235 (22.9) 557/2041 (27.3) 672/2270 (29.6) 713/2426 (29.4) 731/2375 (30.8) 776/2378 (32.6) 787/2294 (34.3) <.01
CNN, n/N (%) 456/1586 (28.8) 481/1897 (25.4) 504/1942 (26.0) 451/2013 (22.4) 406/1943 (20.9) 377/2145 (17.6) 393/2143 (18.3) 385/2194 (17.5) 354/2077 (17.0) <.01
FinMBR, n/N (%) 59/242 (24.4) 52/242 (21.5) 54/245 (22.0) 47/262 (17.9) 64/282 (22.7) 48/244 (19.7) 41/211 (19.4) 37/235 (15.7) 60/236 (25.4) .43
INN, n/N (%) 133/922 (14.4) 136/988 (13.8) 141/1021 (13.8) 136/975 (13.9) 129/975 (13.2) 137/1001 (13.7) 122/905 (13.5) 135/975 (13.8) 165/1027 (16.1) .45
NRNJ, n/N (%) 499/2873 (17.4) 485/2798 (17.3) 571/2963 (19.3) 753/3421 (22.0) 813/3568 (22.8) 858/3628 (23.6) 932/3379 (27.6) 926/3007 (30.8) 699/2485 (28.1) <.01
SEN1500, n/N (%) 219/1574 (13.9) 238/1745 (13.6) 304/1805 (16.8) 250/1602 (15.6) 268/1659 (16.2) 294/1794 (16.4) 292/1679 (17.4) 292/1733 (16.8) 252/1637 (15.4) .01
SNQ, n/N (%) 88/498 (17.7) 98/510 (19.2) 106/489 (21.7) 117/537 (21.8) 100/468 (21.4) 142/561 (25.3) 140/622 (22.5) 178/612 (29.1) 202/675 (29.9) <.01
SwissNeoNet, n/N (%) 39/431 (9.0) 54/464 (11.6) 65/456 (14.3) 75/480 (15.6) 61/494 (12.3) 91/538 (16.9) 66/484 (13.6) 79/517 (15.3) 82/590 (13.9) .02
TuscanNN, n/N (%) NA NA 24/227 (10.6) 21/213 (9.9) 19/166 (11.4) 25/184 (13.6) 25/183 (13.7) 15/162 (9.3) 14/188 (7.4) .54
UKNC, n/N (%) NA 1072/3304 (32.4) 1155/3512 (32.9) 1522/4311 (35.3) 1735/4696 (36.9) 1817/4697 (38.7) 1827/4656 (39.2) 1895/4663 (40.6) 1849/4818 (38.4) <.01
*The P trend was adjusted for birth weight z-score, sex, and multiple births.
Table VIII. ROP treatment rates between 2007 and 2015 in countries participating in iNEO
Countries/regions 2007 2008 2009 2010 2011 2012 2013 2014 2015 P trend*
ANZNN, n/N (%) 84/2447 (3.4) 83/2539 (3.3) 69/2426 (2.8) 57/2248 (2.5) 71/2501 (2.8) 71/2607 (2.7) 67/2539 (2.6) 81/2573 (3.1) 52/2451 (2.1) .02
CNN, n/N (%) 94/1849 (5.1) 94/2200 (4.3) 76/2260 (3.4) 101/2453 (4.1) 79/2306 (3.4) 79/2472 (3.2) 77/2460 (3.1) 89/2478 (3.6) 30/2305 (1.3) <.01
FinMBR, n/N (%) 11/311 (3.5) 8/311 (2.6) 19/304 (6.3) 9/306 (2.9) 15/328 (4.6) 11/268 (4.1) 7/249 (2.8) 6/278 (2.2) 9/272 (3.3) .38
INN, n/N (%) 44/1044 (4.2) 41/1126 (3.6) 39/1188 (3.3) 29/1123 (2.6) 38/1096 (3.5) 31/1163 (2.7) 31/1050 (3.0) 30/1103 (2.7) 29/1157 (2.5) .01
NRNJ, n/N (%) 585/3025 (19.3) 411/2949 (13.9) 500/3082 (16.2) 562/3692 (15.2) 507/3885 (13.1) 576/3936 (14.6) 468/3654 (12.8) 388/3325 (11.7) 327/2795 (11.7) <.01
SEN1500, n/N (%) 97/1983 (4.9) 78/2150 (3.6) 89/2211 (4.0) 91/1910 (4.8) 81/2019 (4.0) 90/2108 (4.3) 96/1956 (4.9) 213/2015 (10.6) 185/1905 (9.7) <.01
SNQ, n/N (%) 26/537 (4.8) 20/554 (3.6) 26/523 (5.0) 33/575 (5.7) 29/511 (5.7) 22/612 (3.6) 17/669 (2.5) 27/659 (4.1) 38/711 (5.3) .62
SwissNeoNet, n/N (%) 7/467 (1.5) 8/509 (1.6) 7/502 (1.4) 12/539 (2.2) 5/537 (0.9) 7/580 (1.2) 6/527 (1.1) 5/563 (0.9) 5/628 (0.8) .08
TuscanNN, n/N (%) NA NA 9/259 (3.5) 7/229 (3.1) 7/187 (3.7) 5/201 (2.5) 7/203 (3.4) 8/179 (4.5) 5/206 (2.4) .88
UKNC, n/N (%) NA 93/3694 (2.5) 114/3890 (2.9) 183/4768 (3.8) 201/5232 (3.8) 194/5200 (3.7) 258/5094 (5.1) 267/5050 (5.3) 269/5203 (5.2) <.01
*The P trend was adjusted for birth weight z score, sex, and multiple births.
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